News

Public · Published

Exosens delivers +23.5% revenue growth in Q3 2026, driven by stronger demand and faster-than-expected capacity ramp-up; Fully on track to meet upgraded 2026 outlook

Exosens reported third-quarter 2026 revenue growth of 23.5%, including 20.5% like-for-like growth. Nine-month group revenue rose 18.0% to €386.9 million, with faster-than-expected capacity ramp-up and stronger demand. The company said it is fully on track to meet its upgraded 2026 outlook.

Published:

Updated:

What happened

Exosens reported third-quarter 2026 revenue growth of 23.5%, including 20.5% like-for-like growth. Nine-month group revenue rose 18.0% to €386.9 million, with faster-than-expected capacity ramp-up and stronger demand. The company said it is fully on track to meet its upgraded 2026 outlook.

Confirmed

Global impact / market context

Faster capacity ramp-up means Exosens can convert more demand into sales sooner, lifting revenue and profit per sale. Its first U.S. order for 1,600 BiNOD night vision systems also opens a new customer channel, which could support future revenue if deliveries repeat.

Analyst inference

Growth spans defense, surveillance, drone and counter-drone applications, and nuclear instrumentation for next-generation small modular reactors. That spread across several end markets means the company is less reliant on one customer budget, while higher volume helps spread fixed production costs over more units.

Analyst inference

What to watch

  1. Exosens said it is fully on track to meet its upgraded 2026 outlook after third-quarter revenue growth accelerated to 23.5%, including 20.5% like-for-like growth. Confirmed
  2. Watch whether the first U.S. Army order for 1,600 BiNOD night vision systems turns into repeat orders, which would show the new complete-systems business line can add lasting revenue. Proposed
  3. Watch whether additional European image intensifier tube capacity keeps running near full use; slower demand or unused capacity would raise cost per unit and pressure the 50.4% adjusted gross margin. Analyst inference

Evidence